Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. Read More on REGN: Regeneron Pharmaceuticals NewsMORE Related Stocks ...
Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase 3 trials expanding its reach to severe allergies. Next: Access Our New, Shockingly Simple 'Alert System' Dupixent ...
The unapproved uses of EYLEA, EYLEA HD, Dupixent, Libtayo and pozelimab noted here are investigational and have not been fully evaluated by any regulatory authority. Cemdisiran, itepekimab ...
Dupixent sales rose 15% to $3.7 billion in ... The company's skin-cancer drug Libtayo delivered a 50% increase in sales to $367 million in the quarter. In January, the company announced results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback